Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.hrthm.2020.03.024 http://scihub22266oqcxt.onion/10.1016/j.hrthm.2020.03.024 32244059!7156157!32244059     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Heart+Rhythm 2020 ; 17 (9): 1456-1462 Nephropedia Template TP {{tp|p=32244059|t=2020. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes |pdf=|usr=}}{{32244059}} gab.com Text SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes JO: Heart Rhythm http://www.kidney.de/pget.php?&tw=1&pmid=32244059 #FOAvip Ever since the first case was reported at the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated coronavirus disease 2019 (COVID-19) has become a serious threat to public health globally in short time. At this point in time, there is no proven effective therapy. The interactions with concomitant disease are largely unknown, and that may be particularly pertinent to inherited arrhythmia syndrome. An arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk of cardiac arrhythmias, either secondary to acquired conditions or comorbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to proarrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances, and use of antiviral drugs. Here, we describe the potential COVID-19-associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic. Twit Text FOAVip SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes ????Heart Rhythm http://www.kidney.de/pget.php?&tw=1&pmid=32244059 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32244059 #FOAvip English Wikipedia <ref>{{Cite pmid|32244059}}</ref> SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes #MMPMID32244059 Wu CI; Postema PG; Arbelo E; Behr ER; Bezzina CR; Napolitano C; Robyns T; Probst V; Schulze-Bahr E; Remme CA; Wilde AAM Heart Rhythm 2020[Sep]; 17 (9): 1456-1462 PMID32244059show ga Ever since the first case was reported at the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated coronavirus disease 2019 (COVID-19) has become a serious threat to public health globally in short time. At this point in time, there is no proven effective therapy. The interactions with concomitant disease are largely unknown, and that may be particularly pertinent to inherited arrhythmia syndrome. An arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk of cardiac arrhythmias, either secondary to acquired conditions or comorbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to proarrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances, and use of antiviral drugs. Here, we describe the potential COVID-19-associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic. |*Betacoronavirus[MESH] |Arrhythmias, Cardiac/*genetics/*therapy/virology[MESH] |COVID-19[MESH] |Coronavirus Infections/*complications/diagnosis/therapy[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/diagnosis/therapy[MESH] |SARS-CoV-2[MESH]SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes (epmc).pdf DeepDyve Pubget Overpricing